← Back to Search

Cancer Vaccine

VP301 (Dose Escalation) for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Virtuoso BINco, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 30 months
Awards & highlights

Study Summary

This trial will test a new drug to treat cancer that has come back or isn't responding to treatment.

Eligible Conditions
  • Multiple Myeloma
  • Solid Tumors
  • Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 30 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 30 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Occurrence of Dose Limiting Toxicity
Occurrence of General Toxicity
Secondary outcome measures
Antidrug and neutralizing antibodies
Best response
Objective response
+3 more
Other outcome measures
Immunoglobulins
Tumor expression

Trial Design

2Treatment groups
Experimental Treatment
Group I: VP301 (Dose Expansion)Experimental Treatment1 Intervention
Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will receive the maximum tolerated dose or recommended phase 2 dose during the Dose Expansion period of the study.
Group II: VP301 (Dose Escalation)Experimental Treatment1 Intervention
Eligible patients will receive VP301 administered as an IV infusion weekly for 6 weeks then every 2 weeks. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.

Find a Location

Who is running the clinical trial?

Virtuoso BINco, Inc.Lead Sponsor

Media Library

VP301 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05698888 — Phase 1
Multiple Myeloma Research Study Groups: VP301 (Dose Escalation), VP301 (Dose Expansion)
Multiple Myeloma Clinical Trial 2023: VP301 Highlights & Side Effects. Trial Name: NCT05698888 — Phase 1
VP301 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05698888 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the VP301 (Dose Escalation) protocol been given the green light by regulatory authorities?

"Due to a lack of data on the safety and efficacy of VP301 (Dose Escalation), our team at Power has assigns it a score of one."

Answered by AI

Can additional participants still join this trial?

"Indeed, this clinical trial is still active and accepting participants. According to the information uploaded on clinicaltrials.gov, it has been running since November 29th 2022 with updates as recent as January 16th 2023."

Answered by AI

What is the size of the cohort participating in this clinical trial?

"Affirmative. Evidenced by information on clinicaltrials.gov, this medical study has initiated its patient recruitment phase after being posted on November 29th 2022 and updated January 16th 2023. 110 individuals will be admitted from 1 trial site."

Answered by AI

What are the prime aims of this clinical trial?

"This clinical trial intends to evaluate the occurrence of dose-limiting toxicities, as well as monitor secondary outcomes such as changes in serum levels and objective/best responses. The study is set to run for an average of 30 months until its completion."

Answered by AI
~1 spots leftby Mar 2025